The Cigna Group Stock Outlook: Is Wall Street Bullish or Bearish?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2025
0mins
Source: NASDAQ.COM
Cigna Group Overview: Cigna Group, a major health services company with a market cap of $84.3 billion, has seen its stock decline by 13.5% over the past year, despite a 9.3% increase year-to-date. The company's performance has been affected by negative sentiment towards health insurers and government actions impacting its Evernorth division.
Analyst Ratings and Projections: Analysts maintain a consensus rating of "Strong Buy" for Cigna, with a mean price target suggesting a potential upside of 25.1% to 34.8%. The company is projected to achieve an 8.6% increase in non-GAAP earnings for the current fiscal year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CI
Wall Street analysts forecast CI stock price to rise
16 Analyst Rating
14 Buy
2 Hold
0 Sell
Strong Buy
Current: 284.740
Low
300.00
Averages
335.63
High
378.00
Current: 284.740
Low
300.00
Averages
335.63
High
378.00
About CI
The Cigna Group is a global health company. The Company has two growth platforms: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services includes its Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the healthcare system to work better and help people live richer, healthier lives. Cigna Healthcare includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical plan services and coordinated solutions to clients and customers. Its Other Operations include corporate-owned life insurance (COLI), the Company's run-off operations and other non-strategic businesses. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, and clinical programs to help its clients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Launches New Program to Enhance Obesity Drug Coverage
- Program Launch: Eli Lilly has introduced the 'Employer Connect' platform aimed at helping more employers cover obesity drugs, addressing a major barrier to patient access and expected to enhance employee drug accessibility.
- Price Transparency: Through this platform, employers can purchase a multi-dose form of Zepbound at a net discounted price of $449 per month, avoiding traditional rebate models, thereby providing clearer visibility on drug pricing for employers.
- Flexible Benefits Design: Employers can choose from 15 different third-party administrators to design benefits tailored to their budget and workforce needs, offering comprehensive obesity management services including telehealth, nutrition, and lifestyle support.
- Government Insurance Coverage: Under landmark deals with President Trump, Medicare will cover obesity drugs for the first time, which is expected to further expand drug accessibility and benefit more patients.
See More
Cigna Group's Financial Ratings Affirmed by AM Best
- Financial Strength Rating: AM Best has affirmed Cigna Group's Financial Strength Rating at A (Excellent) and Long-Term Issuer Credit Ratings at 'a+' (Excellent), reflecting its robust balance sheet and stable operating performance, which is expected to enhance investor confidence.
- Capital Adequacy Advantage: Cigna Life & Health Group's risk-adjusted capitalization is assessed at the highest level, and despite a financial leverage exceeding 43%, strong profitability and liquidity support its debt servicing capacity, ensuring future financial flexibility.
- Revenue Diversification: Cigna's revenue is geographically diversified, primarily from its commercial health insurance business in the U.S., and while the anticipated sale of its Medicare and CareAllies businesses in 2025 may decrease overall revenues, growth in cash flow is expected from its non-insurance operations through Evernorth Health Services.
- Mature Risk Management: Cigna has implemented a comprehensive Enterprise Risk Management (ERM) program that integrates risk management with strategic planning across business units, further enhancing the company's operational stability and market competitiveness.
See More
Cigna Group's Financial Ratings Affirmed by AM Best
- Financial Strength Rating Affirmed: AM Best has affirmed Cigna Group's Financial Strength Rating of A (Excellent) and Long-Term Issuer Credit Ratings of “a+” (Excellent), reflecting its strong balance sheet and operating performance, which is expected to bolster investor confidence.
- Strong Capital Adequacy: Cigna Life & Health Group maintains the highest level of risk-adjusted capitalization as measured by Best’s Capital Adequacy Ratio (BCAR), and despite an elevated financial leverage of over 43%, its robust earnings and liquidity support its debt servicing capacity, ensuring financial flexibility.
- Revenue Diversification: Cigna's revenues are geographically diversified, primarily from the U.S. market, although the anticipated sale of its Medicare and CareAllies businesses in 2025 is expected to decrease overall revenues, its core commercial health products continue to maintain a strong market presence.
- Mature Risk Management: Cigna has implemented a comprehensive Enterprise Risk Management (ERM) program integrated into daily operations and strategic planning, ensuring stable operational performance and risk control capabilities in a complex market environment.
See More
Rising Health Insurance Costs Drag Wage Growth by 20%
- Wage Growth Constraints: The Federal Reserve Bank of New York estimated that rising employee health insurance costs, driven by GLP-1 obesity drugs and other factors, dragged wage growth down by as much as 20% last year, significantly impacting corporate compensation strategies.
- Projected Wage Increases: The research indicated that had health insurance costs not risen, businesses could have offered an average wage increase of approximately 4.7% in 2025, while the actual average wage increase was only 3.8%, highlighting the direct impact of cost pressures on wage policies.
- Rising Insurance Costs: The Kaiser Family Foundation estimated a 6% rise in health insurance costs for 2025, with the Fed survey confirming a 13% increase, reflecting the pressure of soaring healthcare expenditures on corporate operations.
- Corporate Response Strategies: Although not all firms provide health insurance, the study suggests that rising costs are increasing cost pressures for some businesses, thereby limiting wage growth for many workers and affecting overall economic vitality.
See More
Cigna's New CEO Evanko Receives Positive Outlook
- Leadership Transition: Cigna announced that current CEO David M. Cordani will retire on July 1, 2026, to be succeeded by Brian Evanko, the current president and COO, a change widely recognized by Wall Street, with analysts noting Evanko as the 'natural successor' and one of the youngest yet most tenured CEOs in healthcare services.
- Financial Outlook Reaffirmed: On Tuesday, Cigna reaffirmed its projected full-year 2026 consolidated adjusted income from operations of at least $30.25 per share, alongside a pre-tax adjusted income from operations for Evernorth of at least $6.9 billion and for Cigna Healthcare of at least $4.5 billion, indicating strong confidence in future performance.
- Analyst Ratings Maintained: Both Barclays and JPMorgan maintained an 'Overweight' rating on Cigna, with analysts acknowledging that while Evanko's succession timing may surprise some investors, they believe Cigna will continue to perform strongly under his leadership.
- Market Sentiment Analysis: Despite a 9% decline in CI stock over the past 12 months, retail sentiment on Stocktwits remains in the 'bearish' territory, with message volume at normal levels, reflecting a cautious outlook on the company's future performance.
See More
Cigna Group CEO David Cordani to Retire in 2026
- Leadership Transition: Cigna Group announced that CEO David Cordani will retire on July 1, 2026, transitioning to executive chair, with current President and COO Brian Evanko succeeding him, ensuring stability and continuity during the transition period.
- Financial Outlook Reaffirmed: The company reaffirmed its 2026 outlook, projecting adjusted income from operations of at least $30.25 per share, with Evernorth expected to generate at least $6.9 billion and Cigna Healthcare at least $4.5 billion in pre-tax adjusted income, indicating confidence in future performance.
- Stock Price Movement: Cigna's current trading price is $276.70, down $14.15 or 4.87%, reflecting market concerns regarding the leadership change and the overall market environment.
- Collaborative Transition: Cordani and Evanko will work closely during the interim period leading up to the transition, ensuring strategic continuity and execution, thereby enhancing investor confidence in the company's future direction.
See More
Eli Lilly Launches New Program to Enhance Obesity Drug Coverage
- Program Launch: Eli Lilly has introduced the 'Employer Connect' platform aimed at helping more employers cover obesity drugs, addressing a major barrier to patient access and expected to enhance employee drug accessibility.
- Price Transparency: Through this platform, employers can purchase a multi-dose form of Zepbound at a net discounted price of $449 per month, avoiding traditional rebate models, thereby providing clearer visibility on drug pricing for employers.
- Flexible Benefits Design: Employers can choose from 15 different third-party administrators to design benefits tailored to their budget and workforce needs, offering comprehensive obesity management services including telehealth, nutrition, and lifestyle support.
- Government Insurance Coverage: Under landmark deals with President Trump, Medicare will cover obesity drugs for the first time, which is expected to further expand drug accessibility and benefit more patients.
See More
Cigna Group's Financial Ratings Affirmed by AM Best
- Financial Strength Rating: AM Best has affirmed Cigna Group's Financial Strength Rating at A (Excellent) and Long-Term Issuer Credit Ratings at 'a+' (Excellent), reflecting its robust balance sheet and stable operating performance, which is expected to enhance investor confidence.
- Capital Adequacy Advantage: Cigna Life & Health Group's risk-adjusted capitalization is assessed at the highest level, and despite a financial leverage exceeding 43%, strong profitability and liquidity support its debt servicing capacity, ensuring future financial flexibility.
- Revenue Diversification: Cigna's revenue is geographically diversified, primarily from its commercial health insurance business in the U.S., and while the anticipated sale of its Medicare and CareAllies businesses in 2025 may decrease overall revenues, growth in cash flow is expected from its non-insurance operations through Evernorth Health Services.
- Mature Risk Management: Cigna has implemented a comprehensive Enterprise Risk Management (ERM) program that integrates risk management with strategic planning across business units, further enhancing the company's operational stability and market competitiveness.
See More
Cigna Group's Financial Ratings Affirmed by AM Best
- Financial Strength Rating Affirmed: AM Best has affirmed Cigna Group's Financial Strength Rating of A (Excellent) and Long-Term Issuer Credit Ratings of “a+” (Excellent), reflecting its strong balance sheet and operating performance, which is expected to bolster investor confidence.
- Strong Capital Adequacy: Cigna Life & Health Group maintains the highest level of risk-adjusted capitalization as measured by Best’s Capital Adequacy Ratio (BCAR), and despite an elevated financial leverage of over 43%, its robust earnings and liquidity support its debt servicing capacity, ensuring financial flexibility.
- Revenue Diversification: Cigna's revenues are geographically diversified, primarily from the U.S. market, although the anticipated sale of its Medicare and CareAllies businesses in 2025 is expected to decrease overall revenues, its core commercial health products continue to maintain a strong market presence.
- Mature Risk Management: Cigna has implemented a comprehensive Enterprise Risk Management (ERM) program integrated into daily operations and strategic planning, ensuring stable operational performance and risk control capabilities in a complex market environment.
See More
Rising Health Insurance Costs Drag Wage Growth by 20%
- Wage Growth Constraints: The Federal Reserve Bank of New York estimated that rising employee health insurance costs, driven by GLP-1 obesity drugs and other factors, dragged wage growth down by as much as 20% last year, significantly impacting corporate compensation strategies.
- Projected Wage Increases: The research indicated that had health insurance costs not risen, businesses could have offered an average wage increase of approximately 4.7% in 2025, while the actual average wage increase was only 3.8%, highlighting the direct impact of cost pressures on wage policies.
- Rising Insurance Costs: The Kaiser Family Foundation estimated a 6% rise in health insurance costs for 2025, with the Fed survey confirming a 13% increase, reflecting the pressure of soaring healthcare expenditures on corporate operations.
- Corporate Response Strategies: Although not all firms provide health insurance, the study suggests that rising costs are increasing cost pressures for some businesses, thereby limiting wage growth for many workers and affecting overall economic vitality.
See More
Cigna's New CEO Evanko Receives Positive Outlook
- Leadership Transition: Cigna announced that current CEO David M. Cordani will retire on July 1, 2026, to be succeeded by Brian Evanko, the current president and COO, a change widely recognized by Wall Street, with analysts noting Evanko as the 'natural successor' and one of the youngest yet most tenured CEOs in healthcare services.
- Financial Outlook Reaffirmed: On Tuesday, Cigna reaffirmed its projected full-year 2026 consolidated adjusted income from operations of at least $30.25 per share, alongside a pre-tax adjusted income from operations for Evernorth of at least $6.9 billion and for Cigna Healthcare of at least $4.5 billion, indicating strong confidence in future performance.
- Analyst Ratings Maintained: Both Barclays and JPMorgan maintained an 'Overweight' rating on Cigna, with analysts acknowledging that while Evanko's succession timing may surprise some investors, they believe Cigna will continue to perform strongly under his leadership.
- Market Sentiment Analysis: Despite a 9% decline in CI stock over the past 12 months, retail sentiment on Stocktwits remains in the 'bearish' territory, with message volume at normal levels, reflecting a cautious outlook on the company's future performance.
See More
Cigna Group CEO David Cordani to Retire in 2026
- Leadership Transition: Cigna Group announced that CEO David Cordani will retire on July 1, 2026, transitioning to executive chair, with current President and COO Brian Evanko succeeding him, ensuring stability and continuity during the transition period.
- Financial Outlook Reaffirmed: The company reaffirmed its 2026 outlook, projecting adjusted income from operations of at least $30.25 per share, with Evernorth expected to generate at least $6.9 billion and Cigna Healthcare at least $4.5 billion in pre-tax adjusted income, indicating confidence in future performance.
- Stock Price Movement: Cigna's current trading price is $276.70, down $14.15 or 4.87%, reflecting market concerns regarding the leadership change and the overall market environment.
- Collaborative Transition: Cordani and Evanko will work closely during the interim period leading up to the transition, ensuring strategic continuity and execution, thereby enhancing investor confidence in the company's future direction.
See More
